HIMS Form 4: Carroll Harrison Sells Shares, Receives 3,656 RSUs
Rhea-AI Filing Summary
Carroll Patrick Harrison, Chief Medical Officer and a director of Hims & Hers Health, Inc. (HIMS), reported the sale of 60,000 shares of Class A common stock on 08/06/2025 at a weighted average price of $53.5813 per share (sales ranged from $53.19 to $53.97). After the sale his direct beneficial ownership of Class A shares is reported as 169,940 shares.
The filing also discloses a grant of 3,656 Restricted Stock Units (RSUs) that each convert into one share of Class A common stock subject to continuous service; the RSUs vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026. The filer represents the sale price as an average weighted price and offers to provide further allocation details upon request.
Positive
- Transparent disclosure of sale price range and weighted average ($53.19–$53.97; weighted avg $53.5813)
- Clear RSU grant with explicit vesting conditions (earlier of 2026 annual meeting or June 15, 2026)
Negative
- Insider sold 60,000 Class A shares, reducing direct holdings to 169,940 shares
- Grant of 3,656 RSUs implies potential future share issuance upon vesting
Insights
TL;DR: Routine executive sale with concurrent RSU grant; disclosure is complete on price range and vesting, suggesting standard compensation and liquidity activity.
The report documents a voluntary disposition of 60,000 Class A shares with a clear weighted average sale price and an explicit price range, which supports transparent disclosure practices. The subsequent reported direct ownership of 169,940 shares and the separate grant of 3,656 RSUs with a specified vesting trigger indicate standard executive compensation mechanics rather than an unexplained departure or emergency liquidity event. Impactful? Not materially impactful to company fundamentals based on the filing alone.
TL;DR: Insider sale reduces direct holdings but the RSU grant creates potential future share issuance; both are precisely documented in the filing.
From an investor disclosure perspective, the filing supplies the key figures: 60,000 shares sold at a weighted average of $53.5813 (range $53.19–$53.97) and 3,656 RSUs granted that will convert to shares upon vesting. The numbers permit simple pre- and post-transaction ownership reconciliation. Without additional context on total outstanding shares or company-wide dilution, this transaction appears routine and informational rather than materially market-moving.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 3,656 | $0.00 | -- |
| Sale | Class A Common Stock | 60,000 | $53.5813 | $3.21M |
Footnotes (1)
- Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $53.19 - $53.97. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026.
